This is a registry record for an ongoing observational study with no results reported; it describes a planned real-world evidence collection in HER2-low breast cancer but cannot yet support clinical conclusions.
Reported
Planned enrollment2295
Primary outcome measureReal World Time to Next Treatment (rwTTNT1)
Follow-up durationBaseline up to approximately 37 months